The landscape of diabetes management is undergoing a remarkable shift with the emergence of rapidly melting GLP-1 receptor agonists. These novel formulations, designed to rapidly dissolve under the tongue, offer the potential for faster delivery and a lower need for daily injections. This approach could improve patient compliance and maybe lead to

Viking Therapeutics has formed a mutually beneficial alliance with U.S. biopharmaceutical companies to develop and manufacture its GLP-1 drug candidate, VK2735. This marks a significant advancement in securing dependable production capabilities for these vital therapeutic agents. The agreement enables them to handle large-scale peptide manufacturin